Septerna’s (SEPN) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Septerna (NASDAQ:SEPN) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $50.00 price target on the stock.

SEPN has been the topic of several other research reports. Wells Fargo & Company initiated coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $43.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target for the company. Finally, TD Cowen initiated coverage on Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company.

Septerna Stock Performance

NASDAQ:SEPN opened at $11.55 on Tuesday. Septerna has a fifty-two week low of $10.34 and a fifty-two week high of $28.99. The firm’s 50-day simple moving average is $19.60.

Institutional Investors Weigh In On Septerna

Large investors have recently made changes to their positions in the company. New York State Common Retirement Fund bought a new stake in Septerna during the fourth quarter worth approximately $32,000. Legal & General Group Plc bought a new stake in Septerna during the fourth quarter worth approximately $42,000. Ameritas Investment Partners Inc. bought a new stake in Septerna during the fourth quarter worth approximately $45,000. PNC Financial Services Group Inc. bought a new stake in Septerna during the fourth quarter worth approximately $61,000. Finally, SG Americas Securities LLC bought a new stake in Septerna during the fourth quarter worth approximately $185,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.